138.48
+2.57(+1.89%)
Currency In USD
| Previous Close | 135.91 |
| Open | 136.46 |
| Day High | 139.58 |
| Day Low | 136.02 |
| 52-Week High | 207.59 |
| 52-Week Low | 110.04 |
| Volume | 661,168 |
| Average Volume | 1.44M |
| Market Cap | 20.3B |
| PE | 13.25 |
| EPS | 10.45 |
| Moving Average 50 Days | 130.34 |
| Moving Average 200 Days | 139.07 |
| Change | 2.57 |
If you invested $1000 in Biogen Inc. (BIIB) 10 years ago, it would be worth $438.48 as of August 19, 2025 at a share price of $138.48. Whereas If you bought $1000 worth of Biogen Inc. (BIIB) shares 5 years ago, it would be worth $494.61 as of August 19, 2025 at a share price of $138.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
GlobeNewswire Inc.
Aug 11, 2025 11:00 AM GMT
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment period – – Dravet syndrome is a rare genetic disease characterized by refractory seizures and neurodevelopmental impairments,
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
GlobeNewswire Inc.
Jul 30, 2025 3:00 PM GMT
TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
GlobeNewswire Inc.
Jul 25, 2025 11:20 AM GMT
CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorizatio